ElevateBio logo

ElevateBio Funding & Investors

ElevateBio is an operator of a portfolio of cell and gene therapy companies intended to develop, manufacture, and commercialize life-transforming medicines. The company creates a portfolio through partnerships with the world's innovative scientists and inventors as well as it created a centralized facility that integrates all the elements that translate cell and gene therapy R&D into commercially viable therapies quickly and efficiently, enabling patients to get medical products to treat severe diseases. Vikas Sinha, Mitchell Finer, and David Hallal co-founded ElevateBio in Cambridge, Massachusetts in 2017.

elevate.bio

Total Amount Raised: $1,260,000,000

ElevateBio Funding Rounds

  • Series D

    $401,000,000

    Series D Investors

    Novo Nordisk
    EcoR1 Capital
    Woodline Partners
    SoftBank Investment Advisers
    EDBI
    MPM Capital
    F2 Ventures
    Vertex Ventures
    Lee Family Office
    Fidelity Management and Research Company
    Samsara BioCapital
    Surveyor Capital
    Redmile Group
    Emerson Collective
    ITOCHU
    Invus Group
    Matrix Capital Management
  • Angel

    $14,000,000

    Angel Investors

    Qiming Venture Partners
  • Series C

    $525,000,000

    Series C Investors

    EcoR1 Capital
    SoftBank Investment Advisers
    EDBI
    MPM Capital
    F2 Ventures
    Vertex Ventures
    Fidelity Management and Research Company
    Samsara BioCapital
    Surveyor Capital
    Redmile Group
    ITOCHU
    Emerson Collective
    Invus Group
    Matrix Capital Management
  • Series B

    $170,000,000

    Series B Investors

    Redmile Group
    EcoR1 Capital
    Invus Group
    EDBI
    MPM Capital
    F2 Ventures
    Vertex Ventures
    Samsara BioCapital
    Surveyor Capital
  • Series A

    $150,000,000

    Series A Investors

    Redmile Group
    EcoR1 Capital
    UBS Oncology Impact Fund
    Samsara BioCapital
Funding info provided by Diffbot.